Eli Lilly and Co

AbbVie (ABBV) expects its investigational drug Risankizumab to be a transformative therapy for psoriasis.

Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.

As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.

Amgen’s (AMGN) bone health drugs Prolia and Xgeva earn a combined $3 billion in revenue annually.

AbbVie project that Rova-T, a DLL3-targeted antibody conjugate acquired through the acquisition of Stemcentrx, will earn $5 billion in peak sales.

AbbVie hopes to position Imbruvica as a therapy for multiple indications: follicular lymphoma, solid tumor, and diffuse large B-cell lymphoma, among others.

Now in its phase-1 clinical trial, AbbVie’s PF-06647020, an ADC targeting protein kinase 7 could become a major therapy for advanced solid tumors.

Novartis (NVS) has restructured its entire business into two parts: continuing operations and discontinuing operations.

Novartis is exposed to legal risks, including patent litigations, other product-related litigation, commercial litigation, government investigations, and prohibition rules.

Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.

Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue.

In 1Q16, Amgen expects to have data from its Phase 3 clinical trial exploring the use of innovative drug romosozumab for treating post-menopausal osteoporosis.

Abraxane’s sales in the US market fell by 4.2% from 3Q14 to 3Q15, while its sales in the rest of the world’s markets rose by 39.7% in the same time period.

Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D.

Perrigo is a market leader in over-the-counter store-branded products. Its leadership position extends to major geographies such as the US, the UK, and Mexico.

Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.

Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues.

AbbVie’s metabolic and hormonal portfolio offers drugs such as AndroGel, Creon, and Synthroid to address various medical conditions.

Of the 502 constituent stocks of SPY, only 23 recorded positive returns on Wall Street on August 20. Only seven stocks traded at a closing price above their moving averages.

Abbott is organized around a broad portfolio—established pharmaceutical products, diagnostic products, nutritional products, and vascular products.

The risk of losing market share due to losing patents is the highest risk that Eli Lilly and other pharmaceutical companies face.

The human pharmaceutical segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products.

Merck’s Pharmaceuticals division accounted for $36.0 billion, or 85%, of group net sales during 2014.

Leverage ratios determine the company’s ability to repay its debt. Leverage ratios directly affect the credit ratings. Pfizer has good credit ratings.

For a big pharma company like Johnson & Johnson (JNJ), research and development plays a vital role in maintaining a healthy revenue stream.

As a percentage of sales, Johnson & Johnson achieved lower expenses for 2014—compared to 2013. It was able to improve its gross profit margins.